Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Athena puts profit on the horizon

Athena puts profit on the horizon

Changes Athena Neurosciences Inc. made in its product portfolio last week should increase near-term revenues, save money and bring profitability by 1995, according to analysts.

The return to A.H. Robins of world rights to dezinamide (AN051), an anticonvulsant to treat epilepsy, will save ATHN $16 million to $20 million in development costs, according to

Read the full 610 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers